IBD in 2013: enriching the therapeutic armamentarium for IBD.
Copyright policy ) Danese S; Peyrin-Biroulet L;
IBD in 2013: enriching the therapeutic armamentarium for IBD.
In 2013, several new IBD drugs, including golimumab and vedolizumab, have been approved or completed successful programmes, showing efficacy in both Crohn’s disease and ulcerative colitis. In addition, classic IBD drugs have been formulated for colonic delivery, such as budesonide MMX®, which was recently approved for mild-to-moderate ulcerative colitis.
Italy
Biological Factors, Treatment Outcome, Anti-Inflammatory Agents, Antibodies, Monoclonal, Humans, Antibodies, Monoclonal, Humanized, Budesonide, Inflammatory Bowel Diseases
Biological Factors, Treatment Outcome, Anti-Inflammatory Agents, Antibodies, Monoclonal, Humans, Antibodies, Monoclonal, Humanized, Budesonide, Inflammatory Bowel Diseases
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).9 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
selected citations
Citations provided by BIP!
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP! 9
Average
Average
Top 10%
This action will publish the selected files and record in Zenodo. Are you sure you want to proceed?